<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36823441</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5462</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>7-8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Gene therapy</Title><ISOAbbreviation>Gene Ther</ISOAbbreviation></Journal><ArticleTitle>Novel rAAV vector mediated intrathecal HGF delivery has an impact on neuroimmune modulation in the ALS motor cortex with TDP-43 pathology.</ArticleTitle><Pagination><StartPage>560</StartPage><EndPage>574</EndPage><MedlinePgn>560-574</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41434-023-00383-4</ELocationID><Abstract><AbstractText>Recombinant adeno-associated virus (rAAV)-based gene therapies offer&#xa0;an immense opportunity for rare diseases, such as amyotrophic lateral sclerosis (ALS), which is defined by the loss of the upper and the lower motor neurons. Here, we describe generation, characterization, and utilization of a novel vector system, which enables expression of the active form of hepatocyte growth factor (HGF) under EF-1&#x3b1; promoter with bovine growth hormone (bGH) poly(A) sequence and is effective with intrathecal injections. HGF's role in promoting motor neuron survival had been vastly reported. Therefore, we investigated whether intrathecal delivery of HGF would have an impact on one of the most common pathologies of ALS: the TDP-43 pathology. Increased astrogliosis, microgliosis and progressive upper motor neuron loss are important consequences of ALS in the motor cortex with TDP-43 pathology. We find that cortex can be modulated via intrathecal injection, and that expression of HGF reduces astrogliosis, microgliosis in the motor cortex, and help restore ongoing UMN degeneration. Our findings not only introduce a novel viral vector for the treatment of ALS, but also demonstrate modulation of motor cortex by intrathecal viral delivery, and that HGF treatment is effective in reducing astrogliosis and microgliosis in the motor cortex of ALS with TDP-43 pathology.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Gen&#xe7;</LastName><ForeName>Bar&#x131;&#x15f;</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Ave, Chicago, IL, 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Nho</LastName><ForeName>Boram</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, Seoul National University, 1, Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helixmith Co., Ltd., R&amp;D Center, 21, Magokjungang 8-ro 7-gil, Gangseo-gu, Seoul, 07794, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seung</LastName><ForeName>Hana</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Helixmith Co., Ltd., R&amp;D Center, 21, Magokjungang 8-ro 7-gil, Gangseo-gu, Seoul, 07794, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helmold</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Ave, Chicago, IL, 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Huiwon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Helixmith Co., Ltd., R&amp;D Center, 21, Magokjungang 8-ro 7-gil, Gangseo-gu, Seoul, 07794, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;z&#xfc;tok</LastName><ForeName>&#xd6;ge</ForeName><Initials>&#xd6;</Initials><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Ave, Chicago, IL, 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seunghyun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Helixmith Co., Ltd., R&amp;D Center, 21, Magokjungang 8-ro 7-gil, Gangseo-gu, Seoul, 07794, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jinil</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Helixmith Co., Ltd., R&amp;D Center, 21, Magokjungang 8-ro 7-gil, Gangseo-gu, Seoul, 07794, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Sanghyun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Helixmith Co., Ltd., R&amp;D Center, 21, Magokjungang 8-ro 7-gil, Gangseo-gu, Seoul, 07794, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Haneul</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Helixmith Co., Ltd., R&amp;D Center, 21, Magokjungang 8-ro 7-gil, Gangseo-gu, Seoul, 07794, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Nayeon</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, Seoul National University, 1, Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Seung-Shin</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Helixmith Co., Ltd., R&amp;D Center, 21, Magokjungang 8-ro 7-gil, Gangseo-gu, Seoul, 07794, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sunyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, Seoul National University, 1, Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helixmith Co., Ltd., R&amp;D Center, 21, Magokjungang 8-ro 7-gil, Gangseo-gu, Seoul, 07794, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Junghun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4524-0625</Identifier><AffiliationInfo><Affiliation>School of Biological Sciences, Seoul National University, 1, Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea. junghun.lee@helixmith.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helixmith Co., Ltd., R&amp;D Center, 21, Magokjungang 8-ro 7-gil, Gangseo-gu, Seoul, 07794, Republic of Korea. junghun.lee@helixmith.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;zdinler</LastName><ForeName>Hande</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-4125-6013</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Ave, Chicago, IL, 60611, USA. ozdinler@northwestern.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biosciences, Chemistry of Life Processes Institute, Center for Molecular Innovation and Drug Discovery, Center for Developmental Therapeutics, Northwestern University, Evanston, IL, 60208, USA. ozdinler@northwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA060553</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Gene Ther</MedlineTA><NlmUniqueID>9421525</NlmUniqueID><ISSNLinking>0969-7128</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>67256-21-7</RegistryNumber><NameOfSubstance UI="D017228">Hepatocyte Growth Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C066855">HGF protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017228" MajorTopicYN="N">Hepatocyte Growth Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="Y">Motor Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>24</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36823441</ArticleId><ArticleId IdType="doi">10.1038/s41434-023-00383-4</ArticleId><ArticleId IdType="pii">10.1038/s41434-023-00383-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vucic S, Pavey N, Haidar M, Turner BJ, Kiernan MC. Cortical hyperexcitability: Diagnostic and pathogenic biomarker of ALS. Neurosci Lett. 2021;759:136039.</Citation><ArticleIdList><ArticleId IdType="pubmed">34118310</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2021.136039</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Menon P, Ozdinler PH, Kiernan MC, Vucic S. Pathophysiological and diagnostic implications of cortical dysfunction in ALS. Nat Rev Neurol. 2016;12:651&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">27658852</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2016.140</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemon RN. The Cortical &#x201c;Upper Motoneuron&#x201d; in Health and Disease. Brain Sci. 2021;11:619.</Citation><ArticleIdList><ArticleId IdType="pubmed">34066053</ArticleId><ArticleId IdType="pmc">8151778</ArticleId><ArticleId IdType="doi">10.3390/brainsci11050619</ArticleId></ArticleIdList></Reference><Reference><Citation>Genc B, Jara JH, Sanchez SS, Lagrimas AKB, Gozutok O, Kocak N, et al. Upper motor neurons are a target for gene therapy and UCHL1 is necessary and sufficient to improve cellular integrity of diseased upper motor neurons. Gene Ther. 2022;29:178&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">34853443</ArticleId><ArticleId IdType="doi">10.1038/s41434-021-00303-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen GM, Gowing G, Latter J, Chen M, Vit JP, Staggenborg K, et al. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J Neurosci. 2014;34:15587&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">25411487</ArticleId><ArticleId IdType="pmc">4298650</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2037-14.2014</ArticleId></ArticleIdList></Reference><Reference><Citation>Burg T, Bichara C, Scekic-Zahirovic J, Fischer M, Stuart-Lopez G, Brunet A, et al. Absence of Subcerebral Projection Neurons Is Beneficial in a Mouse Model of Amyotrophic Lateral Sclerosis. Ann Neurol. 2020;88:688&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">32588450</ArticleId><ArticleId IdType="pmc">7540428</ArticleId><ArticleId IdType="doi">10.1002/ana.25833</ArticleId></ArticleIdList></Reference><Reference><Citation>Scekic-Zahirovic J, Fischer M, Stuart-Lopez G, Burg T, Gilet J, Dirrig-Grosch S, et al. Evidence that corticofugal propagation of ALS pathology is not mediated by prion-like mechanism. Prog Neurobiol. 2021;200:101972.</Citation><ArticleIdList><ArticleId IdType="pubmed">33309802</ArticleId><ArticleId IdType="doi">10.1016/j.pneurobio.2020.101972</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques C, Burg T, Scekic-Zahirovic J, Fischer M, Rouaux C. Upper and Lower Motor Neuron Degenerations Are Somatotopically Related and Temporally Ordered in the Sod1 Mouse Model of Amyotrophic Lateral Sclerosis. Brain Sci. 2021;11:369.</Citation><ArticleIdList><ArticleId IdType="pubmed">33805792</ArticleId><ArticleId IdType="pmc">7998935</ArticleId><ArticleId IdType="doi">10.3390/brainsci11030369</ArticleId></ArticleIdList></Reference><Reference><Citation>Svendsen CN. Getting the upper hand in ALS. Gene Ther. 2022;29:113&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">35046530</ArticleId><ArticleId IdType="pmc">9013663</ArticleId><ArticleId IdType="doi">10.1038/s41434-022-00314-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen GM, Avalos P, Ma AA, Alkaslasi M, Cho N, Wyss L, et al. Transplantation of Neural Progenitor Cells Expressing Glial Cell Line-Derived Neurotrophic Factor into the Motor Cortex as a Strategy to Treat Amyotrophic Lateral Sclerosis. Stem Cells. 2018;36:1122&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">29656478</ArticleId><ArticleId IdType="doi">10.1002/stem.2825</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61:427&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId><ArticleId IdType="doi">10.1002/ana.21147</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, Levitch D, et al. TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol. 2008;63:535&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18288693</ArticleId><ArticleId IdType="pmc">2747362</ArticleId><ArticleId IdType="doi">10.1002/ana.21344</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">23931993</ArticleId><ArticleId IdType="pmc">4411085</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong LK, Neumann M, Sampathu DM, Lee VM, Trojanowski JQ. TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol. 2007;114:63&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">17492294</ArticleId><ArticleId IdType="doi">10.1007/s00401-007-0226-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Liscic RM, Grinberg LT, Zidar J, Gitcho MA, Cairns NJ. ALS and FTLD: two faces of TDP-43 proteinopathy. Eur J Neurol. 2008;15:772&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">18684309</ArticleId><ArticleId IdType="pmc">2801606</ArticleId><ArticleId IdType="doi">10.1111/j.1468-1331.2008.02195.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia. Curr Opin Neurol. 2008;21:693&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">18989115</ArticleId><ArticleId IdType="pmc">2869081</ArticleId><ArticleId IdType="doi">10.1097/WCO.0b013e3283168d1d</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Sampathu DM, Trojanowski JQ, Lee VM. TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: protein misfolding diseases without amyloidosis. Arch Neurol. 2007;64:1388&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">17923623</ArticleId><ArticleId IdType="doi">10.1001/archneur.64.10.1388</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara JH, Gautam M, Kocak N, Xie EF, Mao Q, Bigio EH, et al. MCP1-CCR2 and neuroinflammation in the ALS motor cortex with TDP-43 pathology. J Neuroinflamm. 2019;16:196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1589-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara JH, Genc B, Stanford MJ, Pytel P, Roos RP, Weintraub S, et al. Evidence for an early innate immune response in the motor cortex of ALS. J Neuroinflamm. 2017;14:129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-017-0896-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz SH, Pinto S, Sebastiao AM, Brites D. Astrocytes in Amyotrophic Lateral Sclerosis. In: Araki T, editor. Amyotroph Lateral Sc. Brisbane (AU): Exon Publications; 2021.</Citation></Reference><Reference><Citation>Van Harten ACM, Phatnani H, Przedborski S. Non-cell-autonomous pathogenic mechanisms in amyotrophic lateral sclerosis. Trends Neurosci. 2021;44:658&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">34006386</ArticleId><ArticleId IdType="pmc">8972039</ArticleId><ArticleId IdType="doi">10.1016/j.tins.2021.04.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Beers DR, Zhao W. Amyotrophic lateral sclerosis is a systemic disease: peripheral contributions to inflammation-mediated neurodegeneration. Curr Opin Neurol. 2021;34:765&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">34402459</ArticleId><ArticleId IdType="doi">10.1097/WCO.0000000000000983</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52:39&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015226</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2006.09.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA. 2009;106:18809&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">19833869</ArticleId><ArticleId IdType="pmc">2762420</ArticleId><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId></ArticleIdList></Reference><Reference><Citation>Handley EE, Pitman KA, Dawkins E, Young KM, Clark RM, Jiang TC, et al. Synapse Dysfunction of Layer V Pyramidal Neurons Precedes Neurodegeneration in a Mouse Model of TDP-43 Proteinopathies. Cereb Cortex. 2017;27:3630&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">27496536</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam M, Jara JH, Kocak N, Rylaarsdam LE, Kim KD, Bigio EH, et al. Mitochondria, ER, and nuclear membrane defects reveal early mechanisms for upper motor neuron vulnerability with respect to TDP-43 pathology. Acta Neuropathol. 2019;137:47&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">30450515</ArticleId><ArticleId IdType="doi">10.1007/s00401-018-1934-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Genc B, Jara JH, Lagrimas AK, Pytel P, Roos RP, Mesulam MM, et al. Apical dendrite degeneration, a novel cellular pathology for Betz cells in ALS. Sci Rep. 2017;7:41765.</Citation><ArticleIdList><ArticleId IdType="pubmed">28165465</ArticleId><ArticleId IdType="pmc">5292972</ArticleId><ArticleId IdType="doi">10.1038/srep41765</ArticleId></ArticleIdList></Reference><Reference><Citation>Genc B, Ozdinler PH. Moving forward in clinical trials for ALS: motor neurons lead the way please. Drug Discov Today. 2014;19:441&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24171950</ArticleId><ArticleId IdType="doi">10.1016/j.drudis.2013.10.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara JH, Genc B, Klessner JL, Ozdinler PH. Retrograde labeling, transduction, and genetic targeting allow cellular analysis of corticospinal motor neurons: implications in health and disease. Front Neuroanat. 2014;8:16.</Citation><ArticleIdList><ArticleId IdType="pubmed">24723858</ArticleId><ArticleId IdType="pmc">3972458</ArticleId><ArticleId IdType="doi">10.3389/fnana.2014.00016</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara JH, Villa SR, Khan NA, Bohn MC, Ozdinler PH. AAV2 mediated retrograde transduction of corticospinal motor neurons reveals initial and selective apical dendrite degeneration in ALS. Neurobiol Dis. 2012;47:174&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">22521461</ArticleId><ArticleId IdType="pmc">4049520</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2012.03.036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara JH, Stanford MJ, Zhu Y, Tu M, Hauswirth WW, Bohn MC, et al. Healthy and diseased corticospinal motor neurons are selectively transduced upon direct AAV2-2 injection into the motor cortex. Gene Ther. 2016;23:272&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">26704722</ArticleId><ArticleId IdType="pmc">4777664</ArticleId><ArticleId IdType="doi">10.1038/gt.2015.112</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardcastle N, Boulis NM, Federici T. AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials. Expert Opin Biol Ther. 2018;18:293&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">29249183</ArticleId><ArticleId IdType="doi">10.1080/14712598.2018.1416089</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Kim S, Lee N, Lee J, Yu SS, Kim JH, et al. Intrathecal delivery of recombinant AAV1 encoding hepatocyte growth factor improves motor functions and protects neuromuscular system in the nerve crush and SOD1-G93A transgenic mouse models. Acta Neuropathol Commun. 2019;7:96.</Citation><ArticleIdList><ArticleId IdType="pubmed">31189468</ArticleId><ArticleId IdType="doi">10.1186/s40478-019-0737-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigaki A, Aoki M, Nagai M, Warita H, Kato S, Kato M, et al. Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model. J Neuropathol Exp Neurol. 2007;66:1037&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">17984685</ArticleId><ArticleId IdType="doi">10.1097/nen.0b013e318159886b</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Funakoshi H, Nakamura T. Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. J Neurosci. 2002;22:6537&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">12151533</ArticleId><ArticleId IdType="pmc">6758174</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.22-15-06537.2002</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y, Kawazoe Y, Sakamoto T, Ojima M, Wang W, Takazawa T, et al. Adenoviral gene transfer of hepatocyte growth factor prevents death of injured adult motoneurons after peripheral nerve avulsion. Brain Res. 2006;1111:187&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">16884699</ArticleId><ArticleId IdType="doi">10.1016/j.brainres.2006.06.104</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebens A, Brose K, Leonardo ED, Hanson MG, Bladt F, Birchmeier C, et al. Hepatocyte growth factor scatter factor is an axonal chemoattractant and a neurotrophic factor for spinal motor neurons. Neuron. 1996;17:1157&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8982163</ArticleId><ArticleId IdType="doi">10.1016/S0896-6273(00)80247-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Maina F, Klein R. Hepatocyte growth factor, a versatile signal for developing neurons. Nature Neurosci. 1999;2:213&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195212</ArticleId><ArticleId IdType="doi">10.1038/6310</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto Y, Livet J, Pollock RA, Garces A, Arce V, deLapeyriere O, et al. Hepatocyte growth factor (HGF/SF) is a muscle-derived survival factor for a subpopulation of embryonic motoneurons. Development. 1997;124:2903&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">9247333</ArticleId><ArticleId IdType="doi">10.1242/dev.124.15.2903</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajroud-Driss S, Christiansen M, Allen JA, Kessler JA. Phase 1/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy. Mol Ther. 2013;21:1279&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">23609019</ArticleId><ArticleId IdType="pmc">3677315</ArticleId><ArticleId IdType="doi">10.1038/mt.2013.69</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler JA, Smith AG, Cha BS, Choi SH, Wymer J, Shaibani A, et al. Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy. Ann Clin Transl Neurol. 2015;2:465&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">26000320</ArticleId><ArticleId IdType="pmc">4435702</ArticleId><ArticleId IdType="doi">10.1002/acn3.186</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyun WB, Hahn W, Kim DS, Yoo WS, Lee SD, Won JH, et al. Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia. Gene Ther. 2010;17:1442&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">20668482</ArticleId><ArticleId IdType="doi">10.1038/gt.2010.101</ArticleId></ArticleIdList></Reference><Reference><Citation>Sufit RL, Ajroud-Driss S, Casey P, Kessler JA. Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:269&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">28166654</ArticleId><ArticleId IdType="doi">10.1080/21678421.2016.1259334</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebens A, Brose K, Leonardo ED, Hanson MG Jr., Bladt F, Birchmeier C, et al. Hepatocyte growth factor/scatter factor is an axonal chemoattractant and a neurotrophic factor for spinal motor neurons. Neuron. 1996;17:1157&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8982163</ArticleId><ArticleId IdType="doi">10.1016/S0896-6273(00)80247-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020;21:255&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">32042148</ArticleId><ArticleId IdType="doi">10.1038/s41576-019-0205-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">30710128</ArticleId><ArticleId IdType="pmc">6927556</ArticleId><ArticleId IdType="doi">10.1038/s41573-019-0012-9</ArticleId></ArticleIdList></Reference><Reference><Citation>During MJ, Leone P. Adeno-associated virus vectors for gene therapy of neurodegenerative disorders. Clin Neurosci. 1995;3:292&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">8914796</ArticleId></ArticleIdList></Reference><Reference><Citation>McCown TJ. Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther. 2005;5:333&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15975010</ArticleId><ArticleId IdType="doi">10.2174/1566523054064995</ArticleId></ArticleIdList></Reference><Reference><Citation>Janson C, McPhee S, Bilaniuk L, Haselgrove J, Testaiuti M, Freese A, et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther. 2002;13:1391&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">12162821</ArticleId><ArticleId IdType="doi">10.1089/104303402760128612</ArticleId></ArticleIdList></Reference><Reference><Citation>Colella P, Ronzitti G, Mingozzi F. Emerging Issues in AAV-Mediated In Vivo Gene Therapy. Mol Ther Methods Clin Dev. 2018;8:87&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">29326962</ArticleId><ArticleId IdType="doi">10.1016/j.omtm.2017.11.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasvoina MV, Genc B, Jara JH, Sheets PL, Quinlan KA, Milosevic A, et al. eGFP expression under UCHL1 promoter genetically labels corticospinal motor neurons and a subpopulation of degeneration-resistant spinal motor neurons in an ALS mouse model. J Neurosci. 2013;33:7890&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">23637180</ArticleId><ArticleId IdType="pmc">3963467</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2787-12.2013</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeili MA, Panahi M, Yadav S, Hennings L, Kiaei M. Premature death of TDP-43 (A315T) transgenic mice due to gastrointestinal complications prior to development of full neurological symptoms of amyotrophic lateral sclerosis. Int J Exp Pathol. 2013;94:56&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">23317354</ArticleId><ArticleId IdType="pmc">3575874</ArticleId><ArticleId IdType="doi">10.1111/iep.12006</ArticleId></ArticleIdList></Reference><Reference><Citation>Genc B, Gautam M, Gozutok O, Dervishi I, Sanchez S, Goshu GM, et al. Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP-43 pathology. Clin Transl Med. 2021;11:e336.</Citation><ArticleIdList><ArticleId IdType="pubmed">33634973</ArticleId><ArticleId IdType="pmc">7898037</ArticleId><ArticleId IdType="doi">10.1002/ctm2.336</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam M, Xie EF, Kocak N, Ozdinler PH. Mitoautophagy: A Unique Self-Destructive Path Mitochondria of Upper Motor Neurons With TDP-43 Pathology Take, Very Early in ALS. Front Cell Neurosci. 2019;13:489.</Citation><ArticleIdList><ArticleId IdType="pubmed">31787882</ArticleId><ArticleId IdType="pmc">6854036</ArticleId><ArticleId IdType="doi">10.3389/fncel.2019.00489</ArticleId></ArticleIdList></Reference><Reference><Citation>Nho B, Lee J, Lee J, Ko KR, Lee SJ, Kim S. Effective control of neuropathic pain by transient expression of hepatocyte growth factor in a mouse chronic constriction injury model. FASEB J. 2018;32:5119&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">29913557</ArticleId><ArticleId IdType="pmc">6113864</ArticleId><ArticleId IdType="doi">10.1096/fj.201800476R</ArticleId></ArticleIdList></Reference><Reference><Citation>Valencia P, Dias AP, Reed R. Splicing promotes rapid and efficient mRNA export in mammalian cells. Proc Natl Acad Sci USA. 2008;105:3386&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">18287003</ArticleId><ArticleId IdType="pmc">2265164</ArticleId><ArticleId IdType="doi">10.1073/pnas.0800250105</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Park EJ, Yu SS, Kim DK, Kim S. Improved expression of vascular endothelial growth factor by naked DNA in mouse skeletal muscles: implication for gene therapy of ischemic diseases. Biochem Biophys Res Commun. 2000;272:230&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10872832</ArticleId><ArticleId IdType="doi">10.1006/bbrc.2000.2758</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin EC, Rottman FM. The 3&#x2019;-flanking sequence of the bovine growth hormone gene contains novel elements required for efficient and accurate polyadenylation. J Biol Chem. 1992;267:16330&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">1644817</ArticleId><ArticleId IdType="doi">10.1016/S0021-9258(18)42005-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Yin Z, Wang Y, Lu Y, Zhang D, Srivastava A, et al. Productive life cycle of adeno-associated virus serotype 2 in the complete absence of a conventional polyadenylation signal. J Gen Virol. 2015;96:2780&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26297494</ArticleId><ArticleId IdType="pmc">4635500</ArticleId><ArticleId IdType="doi">10.1099/jgv.0.000229</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald M, Shenk T. The sequence 5&#x2019;-AAUAAA-3&#x2019;forms parts of the recognition site for polyadenylation of late SV40 mRNAs. Cell. 1981;24:251&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">6113054</ArticleId><ArticleId IdType="doi">10.1016/0092-8674(81)90521-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16:1073&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">18414476</ArticleId><ArticleId IdType="doi">10.1038/mt.2008.76</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Franklin KBJ. The mouse brain in stereotaxic coordinates. Compact 2nd edn. Amsterdam; Boston: Elsevier Academic Press; 2004.</Citation></Reference><Reference><Citation>Bleker S, Sonntag F, Kleinschmidt JA. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J Virol. 2005;79:2528&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">15681453</ArticleId><ArticleId IdType="pmc">546590</ArticleId><ArticleId IdType="doi">10.1128/JVI.79.4.2528-2540.2005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudry E, Vandenberghe LH. Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality. Neuron. 2019;101:839&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">30844402</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.02.017</ArticleId></ArticleIdList></Reference><Reference><Citation>McCraw DM, O&#x2019;Donnell JK, Taylor KA, Stagg SM, Chapman MS. Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20. Virology. 2012;431:40&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22682774</ArticleId><ArticleId IdType="doi">10.1016/j.virol.2012.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. 2017;31:317&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">28669112</ArticleId><ArticleId IdType="pmc">5548848</ArticleId><ArticleId IdType="doi">10.1007/s40259-017-0234-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatakrishnan B, Yarbrough J, Domsic J, Bennett A, Bothner B, Kozyreva OG, et al. Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking. J Virol. 2013;87:4974&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">23427155</ArticleId><ArticleId IdType="pmc">3624325</ArticleId><ArticleId IdType="doi">10.1128/JVI.02524-12</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther. 2010;18:80&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19904234</ArticleId><ArticleId IdType="doi">10.1038/mt.2009.255</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Loo JC, Wright JF. Progress and challenges in viral vector manufacturing. Hum Mol Genet. 2016;25(R1):R42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">26519140</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddv451</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozdinler PH, Benn S, Yamamoto TH, Guzel M, Brown RH Jr., Macklis JD. Corticospinal motor neurons and related subcerebral projection neurons undergo early and specific neurodegeneration in hSOD1G(9)(3)A transgenic ALS mice. J Neurosci. 2011;31:4166&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">21411657</ArticleId><ArticleId IdType="pmc">3643523</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4184-10.2011</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam M, Jara JH, Sekerkova G, Yasvoina MV, Martina M, Ozdinler PH. Absence of alsin function leads to corticospinal motor neuron vulnerability via novel disease mechanisms. Hum Mol Genet. 2016;25:1074&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">26755825</ArticleId><ArticleId IdType="pmc">4764190</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddv631</ArticleId></ArticleIdList></Reference><Reference><Citation>Fil D, DeLoach A, Yadav S, Alkam D, MacNicol M, Singh A, et al. Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease. Hum Mol genet. 2017;26:686&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">28040732</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId><ArticleId IdType="doi">10.1126/science.1134108</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Ludolph AC, Neumann M, Ravits J, Del, Tredici K. Pathological TDP-43 changes in Betz cells differ from those in bulbar and spinal alpha-motoneurons in sporadic amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133:79&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">27757524</ArticleId><ArticleId IdType="doi">10.1007/s00401-016-1633-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Droppelmann CA, Campos-Melo D, Moszczynski AJ, Amzil H, Strong MJ. TDP-43 aggregation inside micronuclei reveals a potential mechanism for protein inclusion formation in ALS. Sci Rep. 2019;9:19928.</Citation><ArticleIdList><ArticleId IdType="pubmed">31882736</ArticleId><ArticleId IdType="pmc">6934605</ArticleId><ArticleId IdType="doi">10.1038/s41598-019-56483-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Miguel L, Frebourg T, Campion D, Lecourtois M. Both cytoplasmic and nuclear accumulations of the protein are neurotoxic in Drosophila models of TDP-43 proteinopathies. Neurobiol Dis. 2011;41:398&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">20951205</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2010.10.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsao W, Jeong YH, Lin S, Ling J, Price DL, Chiang PM, et al. Rodent models of TDP-43: recent advances. Brain Res. 2012;1462:26&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">22608070</ArticleId><ArticleId IdType="pmc">3613131</ArticleId><ArticleId IdType="doi">10.1016/j.brainres.2012.04.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED. Mouse models of frontotemporal dementia. Ann Neurol. 2012;72:837&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">23280835</ArticleId><ArticleId IdType="pmc">3539234</ArticleId><ArticleId IdType="doi">10.1002/ana.23722</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino T, Zerbo RA, Balbi M, Torazza C, Frumento G, Fedele E, et al. Nearly 30 Years of Animal Models to Study Amyotrophic Lateral Sclerosis: A Historical Overview and Future Perspectives. Int J Mol Sci. 2021;22:12236.</Citation><ArticleIdList><ArticleId IdType="pubmed">34830115</ArticleId><ArticleId IdType="pmc">8619465</ArticleId><ArticleId IdType="doi">10.3390/ijms222212236</ArticleId></ArticleIdList></Reference><Reference><Citation>De Giorgio F, Maduro C, Fisher EMC, Acevedo-Arozena A. Transgenic and physiological mouse models give insights into different aspects of amyotrophic lateral sclerosis. Dis Model Mech. 2019;12:dmm037424.</Citation><ArticleIdList><ArticleId IdType="pubmed">30626575</ArticleId><ArticleId IdType="pmc">6361152</ArticleId><ArticleId IdType="doi">10.1242/dmm.037424</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz C. Mouse models of ALS: Past, present and future. Brain Res. 2018;1693:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">29577886</ArticleId><ArticleId IdType="doi">10.1016/j.brainres.2018.03.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrice JR, Gregory-Evans CY, Shaw CA. Animal models of amyotrophic lateral sclerosis: A comparison of model validity. Neural Regen Res. 2018;13:2050&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">30323119</ArticleId><ArticleId IdType="pmc">6199948</ArticleId><ArticleId IdType="doi">10.4103/1673-5374.241445</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Halliday GM, Kril JJ, Gotz J, Hodges JR, Kiernan MC. FTD and ALS-translating mouse studies into clinical trials. Nat Rev Neurol. 2015;11:360&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25939274</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2015.65</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Baloh RH. TDP-43-based animal models of neurodegeneration: new insights into ALS pathology and pathophysiology. Neurodegener Dis. 2011;8:262&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">21124004</ArticleId><ArticleId IdType="doi">10.1159/000321547</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Lee N, Kim S, Lee J, Choi W, Yu SS, et al. Intramuscular delivery of HGF-expressing recombinant AAV improves muscle integrity and alleviates neurological symptoms in the nerve crush and SOD1-G93A transgenic mouse models. Biochem Biophys Res Commun. 2019;517:452&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31376938</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2019.07.105</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi W, Lee J, Lee J, Ko KR, Kim S. Hepatocyte Growth Factor Regulates the miR-206-HDAC4 Cascade to Control Neurogenic Muscle Atrophy following Surgical Denervation in Mice. Mol Ther Nucleic Acids. 2018;12:568&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">30195792</ArticleId><ArticleId IdType="pmc">6077135</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2018.06.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko KR, Lee J, Lee D, Nho B, Kim S. Hepatocyte Growth Factor (HGF) Promotes Peripheral Nerve Regeneration by Activating Repair Schwann Cells. Sci Rep. 2018;8:8316.</Citation><ArticleIdList><ArticleId IdType="pubmed">29844434</ArticleId><ArticleId IdType="pmc">5973939</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-26704-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N, Lee SH, Lee J, Lee MY, Lim J, Kim S, et al. Hepatocyte growth factor is necessary for efficient outgrowth of injured peripheral axons in in vitro culture system and in vivo nerve crush mouse model. Biochem Biophys Rep. 2021;26:100973.</Citation><ArticleIdList><ArticleId IdType="pubmed">33718632</ArticleId><ArticleId IdType="pmc">7933716</ArticleId></ArticleIdList></Reference><Reference><Citation>Sufit RL, Ajroud-Driss S, Casey P, Kessler JA. Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:269&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">28166654</ArticleId><ArticleId IdType="doi">10.1080/21678421.2016.1259334</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler JA, Shaibani A, Sang CN, Christiansen M, Kudrow D, Vinik A, et al. Gene therapy for diabetic peripheral neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor. Clin Transl Sci. 2021;14:1176&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">33465273</ArticleId><ArticleId IdType="pmc">8212761</ArticleId><ArticleId IdType="doi">10.1111/cts.12977</ArticleId></ArticleIdList></Reference><Reference><Citation>Boros BD, Schoch KM, Kreple CJ, Miller TM. Antisense Oligonucleotides for the Study and Treatment of ALS. Neurotherapeutics. 2022;19:1145&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">35653060</ArticleId><ArticleId IdType="pmc">9587169</ArticleId><ArticleId IdType="doi">10.1007/s13311-022-01247-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijboom KE, Brown RH. Approaches to Gene Modulation Therapy for ALS. Neurotherapeutics. 2022;19:1159&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">36068427</ArticleId><ArticleId IdType="pmc">9587165</ArticleId><ArticleId IdType="doi">10.1007/s13311-022-01285-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Duan W, Wang W, Di W, Liu Y, Liu Y, et al. scAAV9-VEGF prolongs the survival of transgenic ALS mice by promoting activation of M2 microglia and the PI3K/Akt pathway. Brain Res. 2016;1648(Pt A):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">27392886</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Duan W, Wang Y, Wen D, Liu Y, Li Z, et al. Intrathecal Delivery of ssAAV9-DAO Extends Survival in SOD1(G93A) ALS Mice. Neurochem Res. 2017;42:986&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">28025800</ArticleId><ArticleId IdType="doi">10.1007/s11064-016-2131-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Kook MG, Byun MR, Lee SM, Lee MH, Lee DH, Lee HB, et al. Anti-apoptotic Splicing Variant of AIMP2 Recover Mutant SOD1-Induced Neuronal Cell Death. Mol Neurobiol. 2023;60:145&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">36242734</ArticleId><ArticleId IdType="doi">10.1007/s12035-022-03073-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust KD, Salazar DL, Likhite S, Ferraiuolo L, Ditsworth D, Ilieva H, et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther. 2013;21:2148&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">24008656</ArticleId><ArticleId IdType="pmc">3863799</ArticleId><ArticleId IdType="doi">10.1038/mt.2013.211</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Yang B, Qiu L, Yang C, Kramer J, Su Q, et al. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet. 2014;23:668&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">24108104</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddt454</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Liu C, Yang C, Wang D, Wu D, Qi Y, et al. Slow Intrathecal Injection of rAAVrh10 Enhances its Transduction of Spinal Cord and Therapeutic Efficacy in a Mutant SOD1 Model of ALS. Neuroscience. 2017;365:192&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">29024785</ArticleId><ArticleId IdType="doi">10.1016/j.neuroscience.2017.10.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Dirren E, Aebischer J, Rochat C, Towne C, Schneider BL, Aebischer P. SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice. Ann Clin Transl Neurol. 2015;2:167&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">25750921</ArticleId><ArticleId IdType="pmc">4338957</ArticleId><ArticleId IdType="doi">10.1002/acn3.162</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P, Kriz J, Gravel M, Soucy G, Bareil C, Gravel C, et al. Adeno-associated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis. Mol Ther. 2014;22:498&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">24394188</ArticleId><ArticleId IdType="pmc">3944333</ArticleId><ArticleId IdType="doi">10.1038/mt.2013.239</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. NEngl J Med. 2020;383:109&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022;387:1099&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">36129998</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveed A, Calderon H. Onasemnogene Abeparvovec (AVXS-101) for the Treatment of Spinal Muscular Atrophy. J Pediatr Pharmacol Ther. 2021;26:437&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">34239394</ArticleId><ArticleId IdType="pmc">8244960</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey RM, Armao D, Nagabhushan Kalburgi S, Gray SJ. Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy. Mol Ther Methods Clin Dev. 2018;9:160&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">29766026</ArticleId><ArticleId IdType="pmc">5948230</ArticleId><ArticleId IdType="doi">10.1016/j.omtm.2018.02.005</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>